Funding news · Nov 13, 2026
Langlai Technology (Createrna) Raises Series B Led by PICC Capital
Langlai Technology (Createrna) Raises Series B Led by PICC Capital
Langlai Technology (朗来科技), which operates as Createrna, has raised a Series B round led by PICC Capital. The Wuhan-based innovative drug developer disclosed the financing on November 13, 2026. The round also drew participation from Qianhai Ark, Vivo Capital, China Merchants Capital, GF Qianhe, Changjiang Capital and NEXTBIO MASTER FUND LP.
What the Company Does
Founded in 2013, Createrna develops oral small-molecule therapies for chronic diseases. Its programs span inflammatory and immunology, cardio-renal, respiratory and ophthalmic indications. The company describes an integrated pipeline of 16 self-developed assets.
Pipeline Highlights
- Lanoracopan hydrochloride (MY008211A): an oral complement factor B inhibitor for paroxysmal nocturnal hemoglobinuria. It is the company's first approved product, cleared in China in June 2026.
- ABBV-848: a clinical-stage asset whose ex-China rights are held by AbbVie, according to the AbbVie Q1 2026 earnings call.
The combination of an approved oral small molecule and a partnered clinical-stage asset gives Createrna both near-term commercial activity and an externally validated pipeline component.
Round Details
| Item | Detail |
|---|---|
| Company | Langlai Technology (朗来科技) / Createrna |
| Headquarters | Wuhan |
| Founded | 2013 |
| Round | Series B |
| Date | November 13, 2026 |
| Lead Investor | PICC Capital |
| Additional Investors | Qianhai Ark, Vivo Capital, China Merchants Capital, GF Qianhe, Changjiang Capital, NEXTBIO MASTER FUND LP |
Why It Matters for Acquisition Watchers
Createrna sits at an unusual point for a China-based biotech: it has moved one asset through approval while maintaining a broad, self-originated pipeline across several chronic-disease categories. The Series B brings in a mix of financial and strategic-oriented investors, led by PICC Capital, alongside Vivo Capital and China Merchants Capital.
For parties tracking the oral small-molecule space in inflammatory/immunology and cardio-renal indications, Createrna's 16-asset pipeline and its approved complement factor B inhibitor make it a name worth monitoring. The AbbVie relationship on ABBV-848 also signals external interest in the company's clinical-stage work.
Summary
Langlai Technology (Createrna) has closed a Series B led by PICC Capital, with participation from Qianhai Ark, Vivo Capital, China Merchants Capital, GF Qianhe, Changjiang Capital and NEXTBIO MASTER FUND LP. The Wuhan company, founded in 2013, develops oral small-molecule therapies for chronic diseases and reports 16 self-developed assets, including its first approved product, lanoracopan hydrochloride, approved in China in June 2026.